Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.
Life Sci
; 48(26): PL123-8, 1991.
Article
em En
| MEDLINE
| ID: mdl-2046473
ABSTRACT
Urinary elimination of unchanged mexiletine, p-hydroxymexiletine (PHM), hydroxymethylmexiletine (HMM) and mexiletine N-glucuronide conjugate (MGC) was investigated before and after treatment with quinidine. All subjects were phenotyped as extensive metabolizers for debrisoquine oxidation. The total recovery of mexiletine and metabolites was significantly reduced after quinidine pretreatment. It is concluded that pretreatment with a very low dose of quinidine inhibits markedly the elimination of both major mexiletine metabolites (PHM and HMM) and likely decreases the overall elimination of mexiletine. That should lead to changes in mexiletine disposition and have clinical consequences during combination therapy with both drugs.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quinidina
/
Debrisoquina
/
Mexiletina
Limite:
Humans
Idioma:
En
Ano de publicação:
1991
Tipo de documento:
Article